Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).

Authors

null

Whitney Paige Kirschbrown

Genentech Inc., South San Francisco, CA

Whitney Paige Kirschbrown , Bei Wang , Ihsan Nijem , Atsushi Ohtsu , Paulo M. Hoff , Manish A. Shah , Lin Shen , Yoon-Koo Kang , Josep Tabernero , Sandhya Girish , Amit Garg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Pharmacology

Clinical Trial Registration Number

NCT01774786

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2564)

DOI

10.1200/JCO.2018.36.15_suppl.2564

Abstract #

2564

Poster Bd #

390

Abstract Disclosures